CZ20033195A3 - Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití - Google Patents

Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití Download PDF

Info

Publication number
CZ20033195A3
CZ20033195A3 CZ20033195A CZ20033195A CZ20033195A3 CZ 20033195 A3 CZ20033195 A3 CZ 20033195A3 CZ 20033195 A CZ20033195 A CZ 20033195A CZ 20033195 A CZ20033195 A CZ 20033195A CZ 20033195 A3 CZ20033195 A3 CZ 20033195A3
Authority
CZ
Czechia
Prior art keywords
formula
indole
compound
solvates
group
Prior art date
Application number
CZ20033195A
Other languages
Czech (cs)
English (en)
Inventor
Kai Schiemann
Henning Böttcher
Joachim Leibrock
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CZ20033195A3 publication Critical patent/CZ20033195A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CZ20033195A 2001-04-30 2002-03-30 Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití CZ20033195A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10121215A DE10121215A1 (de) 2001-04-30 2001-04-30 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden

Publications (1)

Publication Number Publication Date
CZ20033195A3 true CZ20033195A3 (cs) 2004-02-18

Family

ID=7683301

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20033195A CZ20033195A3 (cs) 2001-04-30 2002-03-30 Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití

Country Status (13)

Country Link
US (1) US7279496B2 (enExample)
EP (1) EP1383774B1 (enExample)
JP (1) JP4593879B2 (enExample)
AR (1) AR033624A1 (enExample)
AT (1) ATE394404T1 (enExample)
AU (1) AU2002310904B2 (enExample)
CA (1) CA2445834C (enExample)
CZ (1) CZ20033195A3 (enExample)
DE (2) DE10121215A1 (enExample)
ES (1) ES2303857T3 (enExample)
HU (1) HUP0304046A2 (enExample)
SK (1) SK14472003A3 (enExample)
WO (1) WO2002088143A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656093A (zh) * 2002-05-30 2005-08-17 神经研究公司 3－取代的奎宁环及其用途
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
JP5833804B2 (ja) * 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
AU2007240078B2 (en) * 2006-04-13 2013-07-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
KR20100103799A (ko) * 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
FR3165598A1 (fr) 2024-08-14 2026-02-20 Ultrawatt Élément d’habillage d’une paroi et kit comportant au moins un tel élément

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009565A1 (de) 1990-03-24 1991-09-26 Merck Patent Gmbh Indolderivate
ATE157977T1 (de) 1992-10-13 1997-09-15 Warner Lambert Co Chinoxalinderivate als eaa antagonisten
NZ267081A (en) * 1993-05-13 1997-11-24 Neurosearch As Hetero-fused indole and quinoxaline compounds and medicaments thereof
US5843945A (en) 1993-05-13 1998-12-01 Neurosearch A/S AMPA antagonists and a method of treatment
NZ321172A (en) * 1995-10-03 2000-02-28 Scripps Research Inst CBI analogs of CC-1065 and the duocarmycins
US6147096A (en) * 1998-02-26 2000-11-14 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases

Also Published As

Publication number Publication date
US20040142935A1 (en) 2004-07-22
DE60226428D1 (de) 2008-06-19
AU2002310904B2 (en) 2008-01-10
JP2004529936A (ja) 2004-09-30
EP1383774B1 (en) 2008-05-07
HUP0304046A2 (hu) 2004-04-28
EP1383774A2 (en) 2004-01-28
US7279496B2 (en) 2007-10-09
ATE394404T1 (de) 2008-05-15
AR033624A1 (es) 2003-12-26
SK14472003A3 (sk) 2004-04-06
ES2303857T3 (es) 2008-09-01
JP4593879B2 (ja) 2010-12-08
WO2002088143A2 (en) 2002-11-07
WO2002088143A3 (en) 2003-01-23
DE10121215A1 (de) 2002-10-31
CA2445834C (en) 2011-06-28
CA2445834A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AU2003272316A1 (en) Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans
US7741343B2 (en) 6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
AU2015286049B2 (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof
US7279496B2 (en) Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
AU2002310904A1 (en) Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
JP2018150349A (ja) ヘテロアリール化合物及びその使用方法
AU2007238898A1 (en) Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2002257752A1 (en) 6H-OXAZOLO[4,5-E]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
JPH01172386A (ja) カルボリン誘導体、その製造方法およびカルボリン誘導体を有効成分とする線維素溶解剤
NO123430B (enExample)
MD3649124T2 (ro) Compuși de fluoropiperidină ca antagoniști puri ai receptorului 5-HT6
CZ20032999A3 (cs) Ligandy nikotinacetylcholinového receptoru
EP3428157A1 (en) Selective organic cation transporters inhibitors for the treatment of depressive disorders